Matthew Wiley Insider Trades & Stock Holdings

Chief Commercial Officer · Definium Therapeutics, Inc. · Latest filing Jun 25, 2026

Matthew Wiley, Chief Commercial Officer at Definium Therapeutics, Inc. has 2 Form 4 trades on file since Jun 22, 2026. Open-market activity: 0 purchases ($0) and 1 sale ($129.10K), net -$129.10K. Latest filing: disposed of 2.87K shares of $DFTX on Jun 25, 2026 at $45.03.

Trades on file

2

Open-market bought

$0

Open-market sold

$129.10K

Net open-market

-$129.10K

Latest filing

Jun 25, 2026

All insider trades by Matthew Wiley

Date	Ticker	Type	Shares	Price	Value	Owned after	ΔOwn	1W	1M	6M	Role	Filing	Story
Jun 25, 2026	$DFTX	Sell (Open-market sale) 10b5-1	2.87K	$45.03	$129.10K			-1.3%	-4.8%		Chief Commercial Officer		Read
Jun 22, 2026	$DFTX	Buy (Grant or award)	62.50K	$0	—			+26.9%	+19.1%		Chief Commercial Officer		Read

"Buy" means shares acquired on the Form 4 (including grants and option exercises); "Sell" means shares disposed. 1W / 1M / 6M = how the stock moved after the trade.

Stocks Matthew Wiley traded

• $DFTX

Frequently asked questions

Has Matthew Wiley been buying or selling stock?

Matthew Wiley has 0 open-market purchases and 1 open-market sale on file, net -$129.10K. Grants, option exercises and tax withholding are listed separately because they are not open-market trades.

What was Matthew Wiley's latest insider trade?

disposed of 2.87K shares of $DFTX on Jun 25, 2026 at $45.03.

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.